Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. A phase I/II study of ...
Perioperative analgesic approaches in hepatobiliary cancer malignancies: Experience from a tertiary care centre. Camrelizumab plus rivoceranib as first-line maintenance therapy after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results